
Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.
This white paper from Ascendia Pharma details four factors to consider when selecting a CDMO for your next drug development project.






